Patients who cardiologists see once every few months are getting handed over to pharmacists who can monitor them more frequently and get them to their goals, said Crystal Zhou, PharmD, assistant professor of Clinical Pharmacy at the University of California, San Francisco (UCSF).
Patients who cardiologists see once every few months are getting handed over to pharmacists who can monitor them more frequently and get them to their goals, said Crystal Zhou, PharmD, assistant professor of Clinical Pharmacy at the University of California, San Francisco (UCSF).
Transcript
In what ways are doctors and other health care providers turning to pharmacists more that is leading to an expanded role of pharmacists in care delivery?
So, I feel like our cardiologists are turning more and more over to us for some of their chronic disease state management patients. So those they're not able to see every 1 to 2 weeks. So as an example, someone with uncontrolled hypertension, cardiologists are so busy, they can see the patients maybe every month, every 3 months, maybe even every 6 months, given the patient load.
But when they refer the patients over to our pharmacy team, we're able to see them maybe every 1 to 2 weeks and follow up with the patient, report back to our cardiology providers and monitor that very, very closely. So, I think with the increasing patient load that's become really helpful for our cardiologists.
As more of health care is paid for through value-based payment arrangements, how should pharmacists be included in the care team to meet the metrics tracked in these contracts and improve care to patients?
Billing has kind of been the bane of our existence. It's been really difficult to build for our individual services, and even if we do bill, it's just really not enough.
So, I think value-based care is really the next step to incorporating pharmacists in billing. And maybe a simple example would be if we can manage all of cardiology’s hypertension patients and get them to goal, then the pharmacy team or the cardiology team will get a lump sum that could be shared among pharmacists, and that might be more beneficial than billing per patient or per encounter, as we've thought about in the past.
Right now, at UCSF, we're actually billing in a facility fee. But it's not enough to cover the visit or the salary of the pharmacist, obviously, but it's better than nothing.
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Diving Deep Into Specialty Pharmacy: Insights and Forecasts From IQVIA’s Doug Long
May 1st 2024Doug Long, MBA, vice president of industry relations at IQVIA, covered a bevy of stakeholder investment–related topics in his presentation at AXS24 on trends in specialty pharmacy, chief among them challenges facing the industry, obesity medications, generics and biosimilars, new product launches, and the outlook for the US market.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
OptumRx’s Jon Mahrt Discusses “Irresponsible” Drug Pricing for Products With Multiple Indications
April 30th 2024When the same product comes to market with additional indications, irrational pricing decisions result in ever increasing prices instead of volume translating to lower costs, said Jon Mahrt, MBA, of OptumRX.
Read More